Serotonin syndrome in Parkinson disease.
D015057:1-Naphthylamine / Q000009:adverse effects / Q000031:analogs & derivatives; D003221:Confusion / Q000139:chemically induced; D004347:Drug Interactions; D006801:Humans; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects*; D009207:Myoclonus / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D011985:Receptors, Serotonin / Q000187:drug effects; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D020280:Sertraline; D013577:Syndrome; D014202:Tremor / Q000139:chemically induced
D015057:1-Naphthylamine; D008996:Monoamine Oxidase Inhibitors; D011985:Receptors, Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline